Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

3OED

The structure of the complex between complement receptor CR2 and its ligand complement fragment C3d

Summary for 3OED
Entry DOI10.2210/pdb3oed/pdb
Related1C3D 1GHQ
DescriptorComplement C3, Complement receptor type 2 (3 entities in total)
Functional Keywordscomplement receptor, complement fragment c3d, b cell, immune system
Biological sourceHomo sapiens (human)
More
Cellular locationMembrane; Single-pass type I membrane protein: P01024
Secreted: P20023
Total number of polymer chains4
Total formula weight99153.63
Authors
Isenman, D.E.,van den Elsen, J.M.H. (deposition date: 2010-08-12, release date: 2011-05-11, Last modification date: 2024-10-16)
Primary citationvan den Elsen, J.M.,Isenman, D.E.
A crystal structure of the complex between human complement receptor 2 and its ligand C3d.
Science, 332:608-611, 2011
Cited by
PubMed Abstract: The interaction of complement receptor 2 (CR2)--which is present on B cells and follicular dendritic cells--with its antigen-bound ligand C3d results in an enhanced antibody response, thus providing an important link between the innate and adaptive immune systems. Although a cocrystal structure of a complex between C3d and the ligand-binding domains of CR2 has been published, several aspects of this structure, including the position in C3d of the binding interface, remained controversial because of disagreement with biochemical data. We now report a cocrystal structure of a CR2(SCR1-2):C3d complex at 3.2 angstrom resolution in which the interaction interfaces differ markedly from the previously published structure and are consistent with the biochemical data. It is likely that, in the previous structure, the interaction was influenced by the presence of zinc acetate additive in the crystallization buffer, leading to a nonphysiological complex. Detailed knowledge of the binding interface now at hand gives the potential to exploit the interaction in vaccine design or in therapeutics directed against autoreactive B cells.
PubMed: 21527715
DOI: 10.1126/science.1201954
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3.16 Å)
Structure validation

227111

数据于2024-11-06公开中

PDB statisticsPDBj update infoContact PDBjnumon